Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:01 17/06/2025 BST			After hours 20:59:47
27.16 ^EUR	-1.50%		26.91	-0.92%

05:06pm	Bayer Files for FDA Approval of Gadoquatrane	DJ
08:27am	Bayer Seeks US FDA Nod for MRI Contrast Agent Gadoquatrane	MT

BAYER AG : Goldman Sachs remains Neutral

Published on 05/06/2024 at 09:56, updated on 05/06/2024 at 10:42

Goldman Sachs's research confirms his advice and maintains his neutral opinion on the stock. The target price continues to be set at EUR 31.

Latest news about Bayer AG

Bayer Files for FDA Approval of Gadoquatrane	05:06pm	DJ
Bayer Seeks US FDA Nod for MRI Contrast Agent Gadoquatrane	08:27am	MT
Bayer Files For Approval Of Gadoquatrane In The U.S	07:51am	RE
Bayer Files For Approval Of Gadoquatrane In U.S.	07:34am	RE
DAX Opens Slightly Higher as China and US Ease Export Restrictions	06-12	RE
HSBC Upgrades Bayer to Buy, Boosts PT	06-11	MT
Bayer at annual high after two buy recommendations	06-11	DP
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies	06-11	CI
Bayer strong in pre-market trading after two buy recommendations	06-11	DP
Bayer extends partnership with Broad Institute	06-11	CF
Frankfurt stock market opening: Dax stable after three weaker days	06-11	DP
BAYER : Potatoes may become a precious commodity	06-10
European shares inch up as Lagarde's remarks offset ECB rate cut	06-05	RE
German Stocks Close Higher as ECB Cuts Rates Again	06-05	MT
Bayer Aktiengesellschaft Presents at 2025 dbAccess Global Consumer Conference, Jun-05-2025 08:30 AM	06-05
Bayer, close to the final round(up)?	06-05
Bayer: promising results in diabetic kidney disease	06-05	CF
Goldman Sachs Upgrades Bayer to Buy, Raises PT	06-05	MT
Bayer: shares rise, on Goldman Sachs' upgrade	06-05	CF
Bayer's Trial Shows Improved Kidney Outcomes With Finerenone-Empagliflozin Combo	06-05	MT
Simultaneous Treatment Start With Finerenone And SGLT-2-Inhibitor Demonstrated Positive Data	06-05	RE
European Midday Briefing : Stocks Higher Ahead of Expected Rate Cut	06-05	DJ
Bayer almost back to its high for the year after Goldman's buy recommendation	06-05	DP
Goldman raises Bayer to 'Buy' - target high at 33 euros	06-05	DP
BAYER AG : Goldman Sachs raises its recommendation to Buy	06-05	ZD

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

90,885

Sector

Pharmaceuticals

Calendar

06-17 - Citi European Healthcare Conference

More about the company